Centrus Energy Corporation (NYSE) occupies a strategic position as the only U.S. company licensed by the Nuclear Regulatory Commission to produce High-Assay Low-Enriched Uranium (HALEU), essential for next-generation nuclear reactors. The research report projects significant growth potential amid nuclear energy’s resurgence driven by demand for reliable, climate-friendly power.

Centrus operates through two segments: the LEU segment (84% of 2023 revenue) providing nuclear fuel to commercial plants, and the Technical Solutions segment focused on HALEU production. The company has established key partnerships, including with TerraPower and the Department of Energy, positioning it to capitalize on the projected HALEU market growth to $1 billion annually by 2030.

Financial analysis reveals strong performance with improving liquidity ratios and robust profitability metrics that outpace industry peers. Though the company maintains high leverage with a 2365% debt-to-equity ratio, this is primarily due to negative retained earnings expected to turn positive by 2026.

The research values Centrus using DCF and comparable company methodologies, arriving at similar target prices of $112.73 and $110.90 respectively, suggesting approximately 50% upside from the January 2025 price of $74.05.

Key risks include geopolitical tensions affecting uranium supply chains, potential competition in HALEU production, and regulatory challenges. However, positive catalysts include the Trump administration’s pro-nuclear stance and growing demand for clean energy solutions, supporting a bullish outlook.